Introduction
Alkaptonuria (AKU) is a very rare inherited recessive autosomal metabolic disorder with an estimated prevalence ranging from 1:200.000 to 1:1000000 live births worldwide 1, 2 ; it is caused by homogentisate 1,2-dioxygenase (HGD) deficiency, an enzyme responsible for converting homogentisic acid (HGA) to maleylacetoacetic acid in the tyrosine degradation pathway 1, 2 . The gene encoding HGD has been maped to human chromosome 3q 21-q23 [3] [4] [5] . To date, more than 90 mutations of the HGD gene have been described, reflecting the disorder's clinical variability 2 . The inabitily to metabolise tyrosine and phenylalanine leads to HGA accumulation in the blood; the amount excreted in the urine turns dark brown or black on oxygenation or alkalinization 6, 7 .This typical urine colour occurs early in the disease course but may not be noticed; fresh urine often seem normal and it may take several hours after voiding for the colour changes to occur. Homogentisic acid products resemble melanin and are deposited in the collagen, particularly the cartilage; the resulting tissue colour (ochre) gives the name ochronosis to the process 8 .
The three major features of alkaptonuria are the presence of HGA in the urine, ochronosis (connective tissue bluishblack pigmentation) and spondylarthropathy involving the axial and appendicular skeleton (arthritis of the spine and larger joints). Both synovial and intervertebral joints are affected 9 . Usually, joint symptoms start between the ages of 40 and 50 years. There is a predominance of men relative to women 2:1 10 . Less common manifestations include renal, urethral, and prostatic calculi, cardiovascular abnormalities and valvular disease 7, 11, 12 .
There is no validated assay of HGA in blood. The diagnosis
of alkaptonuria is based on the detection of a significant amount of HGA in the urine by gas chromatography -mass spectrometry analysis. The amount of HGA excreted per day in patients with alkaptonuria is usually between one and eight grams. Identification of biallelic HGD pathogenic variants on molecular genetic testing confirms the diagnosis and allows family studies 6 . Treatment of this metabolic disorder is generally supportive and aimed at preventing or minimizing the effects of ochronotic arthropathy. Knee, hip and shoulder replacement should be a therapeutic option when needed as well as the surgical intervention for prostate and renal stones. Aortic stenosis may necessitate valve replacement too 6 .
Case report
An 81 year old man, with a 5 year history of progressive low back pain and increasing stiffness of the spine, referred to our outpatient clinic. He also mentioned two similar but short-term incidents in his past medical history, starting at the age of 60. From his past medical history, total replacement of both knees and hips in the course of the last 7 years was noted; it was attributed to degenerative arthropathy. He had been diagnosed with Ankylosing Spondylitis and was treated with NSAIDs and Sulfasalazine for the last 5 years without noteworthy amelioration. He was also treated for atrial fibrillation and arterial hypertention.
On initial physical examination, his vital signs were normal. During the head and neck examination a bluish/ black discoloration of the external ears was found and two angular sclera pigmentations were noticed (Figures 1, 2) . On spine examination, no tenderness was found but a severe spine motion limitation was prevalent. The Schober's test was positive and positive Straight leg test was detected bilaterally. The patient mentioned morning stiffness of less than 10 minutes and his back pain exhibited mechanical rather than inflammatory qualities. He also reported bilateral lower limb pain, with right side dominancy. Peripheral joints examination was normal except for the shoulders, where limitation of motion was found in all movement axes.
The blood test results including C-reactive protein, rheumatoid factor and HLA -B27 were negative. Results of all other routine studies were within normal limits. Radiological examination (Plain radiograph and Computing TomographyCTscan) of the thoracic and lumbar spine revealed narrowing of intervertebral disc spaces and prominent wafer-like disc calcification, together with osteophyte formation and calcification of the intervertebral ligaments. Lumbar CT scan showed an orbital narrowing of L5-S1 intervertebral disc with right L5 nerve root pressure, a finding compatible with his lower limbs symptoms (Figures 3, 4 ). An additional lumbar spine CT scan finding was sacroiliac joint calcinosis ( Figure 5 ).
The diagnosis of ankylosing spondylitis was considered on the basis of spinal involvement with anterior ligament calcification and sacroiliitis and large peripheral joints JRPMS involvement (namely hips, knees and shoulders), but the lack of response to treatment together with the presence of extended calcification of all intervertebral discs and concomitant pigmentations of the sclera and ear pointed to the possible diagnosis of ochronosis (alkaptonuria).
Our patient responded to targeted questions on his family and personal history and revealed that his brother had suffered from similar back pain for more than 20 years until he died of a heart attack due to a severe coronary artery disease and aortic valve stenosis at the age of 65. He also mentioned that they had both observed black discoloration of their urine since their childhood. With alkaptonuria being the most likely diagnosis, he was subjected to ultrasonography of kidneys and urinary tract which did not suggest nephrolithiasis and echocardiography where no valvular abnormality was revealed.
In order to establish the diagnosis, we examined the patient's urine, firstly for colour changes -the fresh urine sample was normal in colour and became dark an hour laterand secondly for HGA presentation by the method of gas chromatography. The HGA urine concentration was 27,3 mmol/mmol of creatinine (normally is not detected and in alcaptonurics the average is 3,12 mmol/mmol of creatinine).
We decided to treat the patient with analgesic therapy and vitamin C, 1g daily. Physiotherapy and dietary restrictions with diet low in tyrosine and phenylalanine were also recommended. Despite some reduction in pain, after 6 months of conservative therapy, vitamin C and low protein dietary were not very effective to change the quality of the patient's life.
Discussion
Alkaptonuria is a very rare inborn error of amino acid metabolism due to deficient homogentisic acid (HGA) oxidase enzyme leading to accumulation of HGA in plasma, cartilage, other tissues of human body and its excretion in urine 13, 14 . It has both systemic and peripheral signs and symptoms. Alkaptonuria as a systemic disorder may have other systemic involvement such as cardiac valvular disease or nephrolithiasis other than connective tissue and joint involvement usually present in late middle age 3, 15 . Our patient presented in his early 80s with no systemic manifestation but he had a long standing history of low back pain and progressive stiffness which is common amongst alkaptonurics. In fact, alkaptonuria is often misdiagnosed as severe degenerative axial and peripheral arthropathy (osteoarthritis) or ankylosing spondylitis 16, 17 . Degenerative spondylosis may be seen along the whole of the spine· however the most prominent involvement is in the lumbar region 15, 18 . Tendon thickening and tears and joint effusions usually present later than 30 years of age 2 , as was the story with our case.
Specific findings such as discoloration of the ear cartilage and triangular pigmentation of the sclera combined with the information about dark urine further suggested the diagnosis of alkaptonuria. Non-articular features of ochronosis include bluish discoloration of the ear pinnae, triangular pigmentation of the sclera, and pigmentation over the nose, axillae, and groin and become evident after 30 years of age 17 . Our patient had the characteristic pigmentations since his 40s.
Another feature of the disease is prostatic calculi,-also common in men-and cardiac murmurs, due to deposition of pigment in cardiac valves 17, 19 . Nephrolithiasis and mitral and aortic valvular calcification and regurgitation usually present in late middle age 3 . Increased urine concentration of HGA confirms the diagnosis.
Kara et al 20 summarized the current treatment options including NSAIDs and preparations containing glucosamine and chondroitin sulfate, intra-articular injections of hyaluronic acid and steroids, arthroscopic debridement of the affected joint and arthroplasty 2, 20 . Currently there is no established therapy or prophylactic treatment of alkaptonuria. Treatment is generally supportive and aiming at preventing or minimizing the effects of ochronotic arthropathy. The antioxidant properties of vitamin C have been shown to help slow the conversion of HGA to its pathologic polymeric intermediate 16 .
Dietary restrictions of food containing tyrosine and phenylalanine have been shown to be effective in limiting symptoms of ochronotic arthritis by reducing the production of HGA 21 . Although dietary restriction may be effective in children, it has not shown any benefits in adults 3, 15, 22 . Physical therapy along with NSAID has been successful in improving the symptoms but has not been shown to affect the progression of the underlying disease.
Alternative therapies generally are aimed at reducing HGA production in the liver, replacing the enzyme via liver transplantation, or inhibiting the production of HGA through the administration of Nitisinone 23, 24 . Nitisinone is an herbicide that inhibits 4-hydroxyphenylpyruvate dioxygenase an enzyme responsible for the conversion of 4-hydroxyphenylpyruvate to HGA 24, 25 . It is currently used to treat type 1 hereditary tyrosinemia and its oral administration in ochronotic patients has been shown to decrease urinary HGA secretion. N-acetyl cysteine and vitamin E are being investigated for their demonstrated ability to counteract polymerization and accumulation of HGA in vitro. Probably the ideal therapy would be replacing the missing enzyme as an enzymatic protein or replacing the gene as well.
We decided to treat our patient with analgesic therapy paracetamol and gabapentin 300mg x 3/day, vitamin C 1 g daily, dietary restriction of food protein, especially tyrosine and phenylalanine. The patient's back pain improved considerably in the following 6 months but this treatment was not effective enough to stop the rapid progression of the degenerative arthropathy.
In conclusion, although alkaptonuria is a very rare disease, it should be considered when evaluating low back pain, especially if it is combined with degenerative arthritis in elderly patients. The careful observation of possible ochronotic pigmentation, the detailed history of the patient which may reveal darkening of the urine and the pathognomonic radiological studies will help physicians to establish the correct diagnosis. The rapid progression of the ochronotic arthropathy necessitates the immediate treatment of this metabolic disease so as the degenerative arthropathy will be reduced. Replacing the missing enzyme or the gene consists of a very promising future therapy.
